1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Affimed N.V.
  6. News
  7. Summary
    AFMD   NL0010872420

AFFIMED N.V.

(AFMD)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Affimed Completes Enrollment in Phase 2 Lymphoma Trial; Gets FDA Nod for Another AFM13 Study Protocol

01/06/2022 | 07:20am EDT


© MT Newswires 2022
All news about AFFIMED N.V.
05/16Affimed Presents Data on Innate Cell Engagers AFM24 and AFM28 at 19th Meeting of the So..
GL
05/16Affimed Presents Data on Innate Cell Engagers AFM24 and AFM28 at 19th Meeting of the So..
AQ
05/16Affimed N.V. Presents Data on Innate Cell Engagers Afm24 and Afm28 at 19th Meeting of t..
CI
05/12Affimed to Present Preclinical Data Demonstrating Cytotoxic Activity of its Novel Innat..
GL
05/09Affimed provides update on asco afm13-104 oral presentation
AQ
05/06Affimed Provides Update on ASCO AFM13-104 Oral Presentation
AQ
04/28Affimed announces clinical update and trial in progress posters at the annual meeting o..
AQ
04/27CORRECTING and REPLACING -- Affimed N.V.
AQ
04/27Affimed Announces Clinical Update and Trial in Progress Posters at the Annual Meeting o..
AQ
04/19Affimed announces closing of public offering of common shares and full exercise of unde..
AQ
More news
Analyst Recommendations on AFFIMED N.V.
More recommendations
Financials
Sales 2022 35,7 M 38,2 M 38,2 M
Net income 2022 -101 M -108 M -108 M
Net cash 2022 89,0 M 95,1 M 95,1 M
P/E ratio 2022 -3,90x
Yield 2022 -
Capitalization 457 M 488 M 488 M
EV / Sales 2022 10,3x
EV / Sales 2023 12,1x
Nbr of Employees 197
Free-Float 96,7%
Chart AFFIMED N.V.
Duration : Period :
Affimed N.V. Technical Analysis Chart | AFMD | NL0010872420 | MarketScreener
Technical analysis trends AFFIMED N.V.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 9
Last Close Price 3,06 €
Average target price 11,30 €
Spread / Average Target 269%
EPS Revisions
Managers and Directors
Adolf Hoess Chief Commercial Officer
Angus W. Smith Chief Financial Officer
Thomas O. Hecht Chairman-Supervisory Board
Andreas Harstrick Chief Medical Officer
Arndt Schottelius Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
AFFIMED N.V.-40.76%488
GILEAD SCIENCES, INC.-12.33%79 850
REGENERON PHARMACEUTICALS, INC.7.98%73 473
VERTEX PHARMACEUTICALS22.20%68 632
WUXI APPTEC CO., LTD.-17.77%42 378
BIONTECH SE-36.69%39 666